Lyell Immunopharma Stocks Skyrocket 60% on CAR-T Breakthrough!
Wednesday, Jun 4, 2025 3:08 pm ET1min read
LYEL--
Lyell Immunopharma, Inc. surged 60.96% intraday, as the clinical-stage cell therapy company focuses on developing next-generation chimeric antigen receptor (CAR) T cell product candidates for the treatment of blood cancers and solid tumors. The stock has risen 15.98% over the past five days, despite a 25.70% decline year-to-date.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet